CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”),…
LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”),…
WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
Company to present industry’s first 100-plex, whole slide dataset for deep spatial phenotyping of the…
Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader…
SOLA approach has the potential to be more accurate, scalable, and cost-effective compared to traditional…
WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology…
ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage…
ATLANTA, April 06, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global…
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology…
LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc…
ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage…
– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for…
Topline data anticipated in late Q3/early Q4 A total of 432 subjects are enrolled in…
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq:…
Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared to placebo…
FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…
VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
– Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company –…
Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leaderAaron…
STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…